.jpg?format=webp&width=780)
The article discusses the need for vaccines that incorporate the S proteins of the Omicron and its subvariants (BA.2, BA.4, BA.5) to enhance protection against the coronavirus disease 2019 (COVID-19) pandemic. The authors report preclinical data for a bivalent vaccine formulation that induces robust neutralizing antibody titers against these variants, based on a lipid nanoparticle (LNP)-formulated RNActive® N1-methylpseudouridine (N1mΨ) modified mRNA vaccine (CV0501) encoding the S protein of Omicron BA.1. The protective efficacy of the monovalent CV0501 against live SARS-CoV-2 BA.2 infection is also demonstrated in hamsters. The article concludes by stating that CV0501 has advanced into human Phase 1 clinical trials.
Like
Save
Share